All In MedTech

FDA Clearance Tracker · P120005-S067

Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 7, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 7, 2018

Approved

Time to decision

209 days

Received Oct 10, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P120005-S067
Device name
Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring System
Applicant
Dexcom, Inc.
Applicant location
San Diego, CA
Received
Oct 10, 2017
Decided
May 7, 2018
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P120005

Device type

Device class
Class III

Every decision under product code MDS

FDA's approval statement

As written in FDA's record.

Approval for the addition of a Manufacturing Site for components of the G4 Platinum and G5 Mobile Continuous Glucose Monitoring Systems at your facility located at 232 South Dobson Rd., Mesa, Arizona.

Source documents

Other decisions for Dexcom, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.